Last reviewed · How we verify
RPL554
At a glance
| Generic name | RPL554 |
|---|---|
| Also known as | VMX554, VRP554 |
| Sponsor | Verona Pharma plc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD (PHASE2)
- Effect of Ensifentrine on Sputum Markers of Inflammation in COPD (PHASE2)
- A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease (PHASE2)
- A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (PHASE3)
- Effect of Ensifentrine Treatment on CAT Score (PHASE3)
- A Study of RPL554 in Patients With Cystic Fibrosis (PHASE2)
- A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RPL554 CI brief — competitive landscape report
- RPL554 updates RSS · CI watch RSS
- Verona Pharma plc portfolio CI